Merck & Co Inc (MRK.N) Key Developments | Reuters.com
Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

57.41USD
12:00pm EDT
Change (% chg)

$0.36 (+0.63%)
Prev Close
$57.05
Open
$57.04
Day's High
$57.41
Day's Low
$56.92
Volume
771,216
Avg. Vol
2,841,495
52-wk High
$60.06
52-wk Low
$45.70

Latest Key Developments (Source: Significant Developments)

Merck, Premier Inc collaborate to improve care for osteoporosis patients
9:28am EDT 

Merck & Co In : Merck And Premier Inc collaborate to prevent fractures for osteoporosis patients .Financial terms of agreements were not disclosed.  Full Article

Merck's Keytruda shows superior progression-free, overall survival in lung cancer patients
Thursday, 16 Jun 2016 06:45am EDT 

Merck & Co Inc : Merck's keytruda® (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer . Keynote-024 trial met its primary endpoint . Safety profile of keytruda in this trial was consistent with that observed in previously reported studies in patients with advanced nsclc . Based on these results, an independent data monitoring committee (dmc) has recommended that trial be stopped . Independent data monitoring committee recommended patients receiving chemotherapy in keynote-024 be offered opportunity to receive keytruda. .Keytruda was superior compared to chemotherapy for primary endpoint of progression-free survival, and secondary endpoint of overall survival.  Full Article

Merck to acquire Afferent Pharmaceuticals
Thursday, 9 Jun 2016 05:07pm EDT 

Merck & Co Inc : Merck to acquire Afferent Pharmaceuticals . Signed a definitive agreement under which Merck will acquire Afferent Pharmaceuticals . Under terms, Merck, through unit, to acquire outstanding stock of Afferent for an upfront payment of $500 million in cash .Afferent shareholders will be eligible to receive a total of up to an additional $750 million associated with attainment of certain milestones.  Full Article

Merck Global Health Innovation Fund hikes stake in OpGen to 37.5 pct from 11.8 pct
Friday, 27 May 2016 04:01pm EDT 

Merck Global Health Innovation Fund, Llc : Merck Global Health Innovation Fund, Llc reports a stake of 37.5 percent in Opgen Inc as of May 19, 2015 .Merck Global Health Innovation Fund, Llc had previously reported a 11.80 pct stake in Opgen Inc - SEC filing.  Full Article

Merck sets quarterly dividend of 46 cents per share
Tuesday, 24 May 2016 02:35pm EDT 

Merck & Co Inc :Sets quarterly dividend of $0.46 per share.  Full Article

Merck names Sanat Chattopadhyay president of Merck Manufacturing Division
Monday, 7 Mar 2016 04:30pm EST 

Merck MRK.N:Names Sanat Chattopadhyay president of Merck Manufacturing Division; will succeed Willie Deese who will retire.Deese will retire on June 1, 2016.Says Chattopadhyay joined Merck in 2009 and currently serves as senior vice president of global Manufacturing Operations.  Full Article

Merck & Co Inc's investigational once-daily formulation of ISENTRESS meets primary and secondary endpoints in pivotal phase 3 study
Monday, 22 Feb 2016 08:00am EST 

Merck & Co Inc:Says its investigational once-daily formulation of ISENTRESS meets primary and secondary endpoints in pivotal phase 3 study.Says 1200 mg raltegravir was statistically non-inferior to the marketed formulation approved dose.  Full Article

Merck & Co Inc gives FY 2016 guidance
Wednesday, 3 Feb 2016 06:45am EST 

Merck & Co Inc:Expects FY 2016 GAAP EPS to be between $1.96 and $2.23.Expects FY 2016 expects non-GAAP EPS to be between $3.60 and $3.75, Including an about 4 Percent negative Impact from foreign exchange.Anticipates FY 2016 worldwide sales to be between $38.7 billion and $40.2 billion, Including an about 3 percent negative impact from foreign exchange.  Full Article

Merck announces FDA acceptance of Biologics License Application for Bezlotoxumab
Wednesday, 27 Jan 2016 08:30am EST 

Merck & Co Inc:Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence.Says the FDA granted Priority Review for bezlotoxumab, with a Prescription Drug User Fee Act (PDUFA) action date of July 23, 2016.Company also has filed a marketing authorization application for bezlotoxumab with the European Medicines Agency (EMA) that is currently under review.  Full Article

Merck & Co Inc acquires IOmet Pharma
Monday, 11 Jan 2016 04:08pm EST 

Merck & Co Inc:Has acquired IOmet.Under terms of the agreement, Merck, through a subsidiary, will acquire IOmet, including its comprehensive pre-clinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors.Based on the transaction, IOmet will become a wholly owned subsidiary of Merck.Financial terms of the acquisition were not disclosed.  Full Article

BRIEF-Merck, Premier Inc collaborate to improve care for osteoporosis patients

* Merck And Premier Inc collaborate to prevent fractures for osteoporosis patients